This HTML5 document contains 240 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
n11http://dx.doi.org/10.1158/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q30253017
rdf:type
wikibase:Item
schema:description
2017年论文 2017年論文 article científic مقالهٔ علمی scientific article artículo científico publicado en 2017 სამეცნიერო სტატია tudományos cikk vedecký článok artigo científico 2017년 논문 2017年論文 videnskabelig artikel (udgivet 2017) 2017年论文 2017年の論文 מאמר מדעי мақолаи илмӣ บทความทางวิทยาศาสตร์ tieteellinen artikkeli articol științific 2017年論文 2017年论文 سائنسی مضمون artikulong pang-agham artykuł naukowy επιστημονικό άρθρο wetenschappelijk artikel ২০১৭-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ scienca artikolo научная статья 2017 թուականի Մարտին հրատարակուած գիտական յօդուած 2017 թվականի մարտին հրատարակված գիտական հոդված vitenskapelig artikkel 2017年論文 2017年论文 teaduslik artikkel artigo científico (publicado na 2017) مقالة علمية (نشرت في 7-3-2017) научни чланак 2017 nî lūn-bûn vědecký článek article scientifique (publié 2017) articolo scientifico vitskapeleg artikkel 2017年论文 article scientific mokslinis straipsnis naučni članak 2017年論文 2017年论文 bài báo khoa học artigo científico (publicado na 2017) vetenskaplig artikel artículu científicu espublizáu en 2017 bilimsel makale artikull shkencor наукова стаття, опублікована в березні 2017 научни чланак wissenschaftlicher Artikel мақолаи илмӣ научна статия
p:P577
wds:Q30253017-0F199800-4790-4E46-85E7-C38176D7EC23
wdt:P577
2017-03-07T00:00:00Z
p:P407
wds:Q30253017-846B65AC-333C-43C6-8D1F-AF91FE2804F0
wdt:P407
wd:Q1860
p:P2860
wds:Q30253017-0075597A-B2B3-4A36-992A-574EBAC58567 wds:Q30253017-FCDBBE44-EF4E-4501-854A-5DC0FAE59C5F wds:Q30253017-FDF4C22A-2267-4981-ACBC-5765A4A654A7 wds:Q30253017-C890E10F-2B26-4EAB-8C31-2CE44008314F wds:Q30253017-C89C342B-603C-44DF-999C-9F8EF4AAB453 wds:Q30253017-CD58F9C7-221A-4944-901E-8FD262D66789 wds:Q30253017-BF465A78-1ECB-4025-8270-309AC160FA68 wds:Q30253017-9ED38338-AA6B-4E71-96A9-E0777EC0C3E3 wds:Q30253017-9F96B83A-99CB-4ED8-816F-9FD0439D8D74 wds:Q30253017-AA66C043-8D1B-479D-85C3-4BCC29A0B461 wds:Q30253017-D0AD79F7-E250-47BB-A7C5-D6C9EB653CF5 wds:Q30253017-AB770ACC-DB10-4AA1-ACC9-C477DD095A8C wds:Q30253017-D367389E-3D26-4D56-8920-4D680294AA77 wds:Q30253017-9ADD2F11-86D0-4D6C-8500-712B585B661A wds:Q30253017-D9C4AC53-FCD0-4172-9614-1CEF4A4FC042 wds:Q30253017-9C15587F-C4C9-4C6C-9978-8DEE535F1712 wds:Q30253017-9C273F0F-7058-4F12-A526-A69DB3D0AC03 wds:Q30253017-B6A3BAF1-5690-4DAA-AAB1-153E884728E0 wds:Q30253017-B718FAAC-E58C-4209-BD3C-AA1E293CDF9C wds:Q30253017-B7760FBC-2532-48A2-93EE-B6F0FD2DE487 wds:Q30253017-AE142CE6-21B5-4CC7-860F-CB8E2405C139 wds:Q30253017-B32DFC9D-B0B7-4D18-B1D9-D300434D75BC wds:Q30253017-B569F337-6575-45B6-BCDA-6FB14AE37BB8 wds:Q30253017-6E0BB207-B3CF-4832-92C5-577FDD1B75D6 wds:Q30253017-714822DB-B4E5-41FF-AB19-71E8A66867C9 wds:Q30253017-69031F07-56DC-422D-9EEC-E8020E3850ED wds:Q30253017-8DBFFDC0-EA2A-4D47-A1EF-48A32E805BEA wds:Q30253017-992641A6-3C36-46AE-AA01-C421DE704E6B wds:Q30253017-791D3254-4663-45CA-A863-C72037542B6B wds:Q30253017-45F8F225-E440-4C2C-9D80-C00378BF205E wds:Q30253017-30BE188B-98D7-4FAF-9F7C-0AE9854CD714 wds:Q30253017-404C476E-DB34-4D81-BCD9-388C72011850 wds:Q30253017-413C711F-E951-473D-9861-FEFF4DF5026C wds:Q30253017-5C670037-AA26-40D2-8554-F102B6D01D46 wds:Q30253017-607E7AA5-90E7-4B83-A787-DA9D1FABDEE4 wds:Q30253017-51C6917C-989C-4CC4-BE40-4A95EBDD07EC wds:Q30253017-5A6117C9-585A-4D84-9D23-F319F07A6189 wds:Q30253017-08500C48-36FA-4007-8170-5A3A94EE0FE3 wds:Q30253017-08A9774E-EEFA-4515-8DB0-0A09E35458D7 wds:Q30253017-0E20AC46-E04A-4DAB-9B0F-72F59BDDC3C0 wds:Q30253017-0780661B-BC49-4437-B233-52AC7046DDA7 wds:Q30253017-28334982-B40B-4AB1-A746-B4095385C6A9 wds:Q30253017-3096593B-63A7-4D53-8E87-4FA88DE3A4DD wds:Q30253017-1FC0E790-4172-4240-B7A3-04320752908B
wdt:P2860
wd:Q30418169 wd:Q44462995 wd:Q36204215 wd:Q29547614 wd:Q27860742 wd:Q27853147 wd:Q43280969 wd:Q34639174 wd:Q39130461 wd:Q29617680 wd:Q24630844 wd:Q40243368 wd:Q51022930 wd:Q29614870 wd:Q35745252 wd:Q29619914 wd:Q37705395 wd:Q46771645 wd:Q36793779 wd:Q34658655 wd:Q54516956 wd:Q85353345 wd:Q34550194 wd:Q27860709 wd:Q36142926 wd:Q27860519 wd:Q52907227 wd:Q34483460 wd:Q50666942 wd:Q30872351 wd:Q27304609 wd:Q29547262 wd:Q29615052 wd:Q29614489 wd:Q37153948 wd:Q35078761 wd:Q42591658 wd:Q46389190 wd:Q35952250 wd:Q30688271 wd:Q36898974 wd:Q35889643 wd:Q29547193 wd:Q34172008
p:P2093
wds:Q30253017-5C43AF6E-6EC1-4FB1-B624-DAFF57C46D99 wds:Q30253017-6723CFC7-E4A9-4807-A213-D8ABC85F3A07 wds:Q30253017-66B28C65-D36E-4BF6-94ED-CF7712D64C17 wds:Q30253017-6D5679D2-5BF6-4205-BE06-21AFC3FC78C8 wds:Q30253017-6DF85DB2-E5C0-43C5-9CDE-F1C0C8F63855 wds:Q30253017-8525C1BD-F754-47BE-8F0B-91B9953B3754 wds:Q30253017-7C2EAFDB-BF83-4BC9-B3A9-0B22AD513058 wds:Q30253017-90023B4A-1C0E-4A7E-822A-C2F1A49916F3 wds:Q30253017-8A3039AC-DF94-4945-81E5-CD5847CB0AFF wds:Q30253017-C3113EBD-D5FC-474C-B5F3-D79D1119D61B wds:Q30253017-BE006CA2-8A15-49D2-91BF-57BBD8CED54E wds:Q30253017-D4D08E73-A863-4484-8AE0-AECF862E3500 wds:Q30253017-EF72AFA7-EE73-4A91-9898-4A6695355497 wds:Q30253017-1BFE9702-1A6C-48EB-BE62-7AC9B029F010 wds:Q30253017-15005C07-4063-406E-928B-CB5E62C0ED62 wds:Q30253017-4293DE1E-CB38-479B-A2C9-5C4D5591AB4B wds:Q30253017-59F3E49B-CAA7-4768-A412-0C8124CF5612 wds:Q30253017-54164C13-9AE2-4884-A95A-C6BA71C340F2
wdt:P2093
Ingrid A Mayer Patrick M Dillon Aditya Bardia Jennifer M Rosenbluth Bojana Jovanović Jenny C Chang Andres Forero-Torres Erica L Mayer M Gabriela Kuba Violeta Sanchez Brian D Lehmann Sheau-Chiann Chen Kimberly C Johnson Vandana G Abramson Melinda E Sanders Ingrid M Meszoely Ana M Grau Yu Shyr
rdfs:label
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons
skos:prefLabel
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons
schema:name
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons
p:P50
wds:Q30253017-B6E808AF-A9B7-433D-B244-C194235B7776 wds:Q30253017-2F182C03-26AC-4E18-A79E-978122B82903 wds:Q30253017-0B640B88-E09D-455B-9528-457B18D00286 wds:Q30253017-606E6F75-591C-42B2-86A0-F88F57A69161 wds:Q30253017-4F2896CC-6982-4A12-ACAC-807FFFDBD63B wds:Q30253017-F937BDAA-4B34-4EAF-A52B-E76B689D80D6
wdt:P50
wd:Q88735105 wd:Q90280624 wd:Q84791239 wd:Q42122644 wd:Q56851379 wd:Q41526405
p:P1476
wds:Q30253017-02FBD9A0-6573-4225-A60D-75F68A0A8763
wdt:P1476
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Respons
p:P304
wds:Q30253017-FC6CFDA6-B30C-44DD-84B7-422B831347EC
wdt:P304
4035-4045
p:P31
wds:Q30253017-46C31303-AA44-463A-8425-8501AA838A5A
wdt:P31
wd:Q13442814
p:P921
wds:Q30253017-60B8F248-379F-4F54-BE40-07DC7A55CECC wds:Q30253017-C7CEE369-D741-44D1-B50A-9CF660D39FDA wds:Q30253017-3E0F898C-F3E3-48CC-9403-B92BDC1AC3B0 wds:Q30253017-2AE9E06D-1626-4770-BEF0-6FA06A96F379
wdt:P921
wd:Q7843332 wd:Q5205747 wd:Q423762 wd:Q412415
p:P698
wds:Q30253017-E5D90A79-7B4C-4EBA-9D66-C49B0FA1F403
wdtn:P698
n12:28270498
wdt:P698
28270498
p:P1433
wds:Q30253017-076E639B-D4F5-4813-974C-1B374AA92F43
wdt:P1433
wd:Q332253
p:P433
wds:Q30253017-99752163-820D-43BB-A6C4-B750B493D799
p:P478
wds:Q30253017-033ACCAF-956B-4592-8BF0-E25672885751
wdt:P433
15
wdt:P478
23
p:P356
wds:Q30253017-C61B6BCE-2C9B-48A7-BA6C-B5F8BDCBE3E8
wdtn:P356
n11:1078-0432.CCR-16-3055
wdt:P356
10.1158/1078-0432.CCR-16-3055
skos:altLabel
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response
p:P932
wds:Q30253017-AD9262C4-ECAD-40DA-AA61-2F7BE7163508
wdt:P932
5540799